The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)

P. Cahn; K. Ruxrungtham; B. Gazzard; R.S. Diaz; A. Gori; D.P. Kotler; A. Vriesema; N.A. Georgiou; J. Garssen; M. Clerici; J.M.A. Lange

doi:10.1093/cid/cit171

The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)

P. Cahn, K. Ruxrungtham, B. Gazzard, R.S. Diaz, A. Gori, D.P. Kotler, A. Vriesema, N.A. Georgiou, J. Garssen, M. Clerici, J.M.A. Lange

Pharmacology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits.Methods In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretroviral therapy, with CD4+T-cell counts

Original language	English
Pages (from-to)	139-146
Number of pages	8
Journal	Clinical Infectious Diseases
Volume	57
Issue number	1
DOIs	https://doi.org/10.1093/cid/cit171
Publication status	Published - 1 Jul 2013

Keywords

CD4 decline
immune activation
immunonutrition
NR100157
ISRCTN81868024
immunomodulating agent
nr 100157
unclassified drug
virus RNA
adult
article
CD4 lymphocyte count
CD4+ CD25+ T lymphocyte
CD4+ T lymphocyte
controlled study
diarrhea
double blind procedure
drug safety
drug tolerability
female
human
Human immunodeficiency virus 1 infection
immunomodulation
lymphocyte activation
major clinical study
male
multicenter study
nonhodgkin lymphoma
pilot study
priority journal
randomized controlled trial
treatment outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cit171

Fingerprint

Dive into the research topics of 'The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)'. Together they form a unique fingerprint.

Cite this

Cahn, P., Ruxrungtham, K., Gazzard, B., Diaz, R. S., Gori, A., Kotler, D. P., Vriesema, A., Georgiou, N. A., Garssen, J., Clerici, M., & Lange, J. M. A. (2013). The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clinical Infectious Diseases, 57(1), 139-146. https://doi.org/10.1093/cid/cit171

@article{e7085c9caaff4173815336283dcdd045,

title = "The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)",

abstract = "Background The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits.Methods In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretroviral therapy, with CD4+T-cell counts",

keywords = "CD4 decline, immune activation, immunonutrition, NR100157, ISRCTN81868024, immunomodulating agent, nr 100157, unclassified drug, virus RNA, adult, article, CD4 lymphocyte count, CD4+ CD25+ T lymphocyte, CD4+ T lymphocyte, controlled study, diarrhea, double blind procedure, drug safety, drug tolerability, female, human, Human immunodeficiency virus 1 infection, immunomodulation, lymphocyte activation, major clinical study, male, multicenter study, nonhodgkin lymphoma, pilot study, priority journal, randomized controlled trial, treatment outcome",

author = "P. Cahn and K. Ruxrungtham and B. Gazzard and R.S. Diaz and A. Gori and D.P. Kotler and A. Vriesema and N.A. Georgiou and J. Garssen and M. Clerici and J.M.A. Lange",

year = "2013",

month = jul,

day = "1",

doi = "10.1093/cid/cit171",

language = "English",

volume = "57",

pages = "139--146",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

Cahn, P, Ruxrungtham, K, Gazzard, B, Diaz, RS, Gori, A, Kotler, DP, Vriesema, A, Georgiou, NA, Garssen, J, Clerici, M & Lange, JMA 2013, 'The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)', Clinical Infectious Diseases, vol. 57, no. 1, pp. 139-146. https://doi.org/10.1093/cid/cit171

The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). / Cahn, P.; Ruxrungtham, K.; Gazzard, B. et al.
In: Clinical Infectious Diseases, Vol. 57, No. 1, 01.07.2013, p. 139-146.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)

AU - Cahn, P.

AU - Ruxrungtham, K.

AU - Gazzard, B.

AU - Diaz, R.S.

AU - Gori, A.

AU - Kotler, D.P.

AU - Vriesema, A.

AU - Georgiou, N.A.

AU - Garssen, J.

AU - Clerici, M.

AU - Lange, J.M.A.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits.Methods In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretroviral therapy, with CD4+T-cell counts

AB - Background The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits.Methods In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretroviral therapy, with CD4+T-cell counts

KW - CD4 decline

KW - immune activation

KW - immunonutrition

KW - NR100157

KW - ISRCTN81868024

KW - immunomodulating agent

KW - nr 100157

KW - unclassified drug

KW - virus RNA

KW - adult

KW - article

KW - CD4 lymphocyte count

KW - CD4+ CD25+ T lymphocyte

KW - CD4+ T lymphocyte

KW - controlled study

KW - diarrhea

KW - double blind procedure

KW - drug safety

KW - drug tolerability

KW - female

KW - human

KW - Human immunodeficiency virus 1 infection

KW - immunomodulation

KW - lymphocyte activation

KW - major clinical study

KW - male

KW - multicenter study

KW - nonhodgkin lymphoma

KW - pilot study

KW - priority journal

KW - randomized controlled trial

KW - treatment outcome

U2 - 10.1093/cid/cit171

DO - 10.1093/cid/cit171

M3 - Article

SN - 1058-4838

VL - 57

SP - 139

EP - 146

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP et al. The immunomodulatory nutritional intervention NR100157 reduced CD4+T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clinical Infectious Diseases. 2013 Jul 1;57(1):139-146. doi: 10.1093/cid/cit171